Paraneoplastic sarcoidosis: a review

Herron, Malcolm; Chong, Sy Giin; Gleeson, Laura E.; Nicholson, Siobhan; Fahy, Ruairi J.

doi:10.1093/qjmed/hcz207

Cited by 12 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though the aetiology of sarcoidosis is unclear, immune cross‐reaction to an infectious agent has been postulated in genetically susceptible people 2,3 . Sarcoid‐like reactions are also observed in association with inflammatory processes such as malignancy, following occupational exposures, and as adverse reactions to immunotherapy drugs 4,5 . Here we describe three cases that support the theory of COVID‐19 infection as a potential trigger for sarcoidosis.…”

Section: Discussionmentioning

confidence: 57%

“…2,3 Sarcoid-like reactions are also observed in association with inflammatory processes such as malignancy, following occupational exposures, and as adverse reactions to immunotherapy drugs. 4,5 Here we describe three cases that support the theory of COVID-19 infection as a potential trigger for sarcoidosis. While the absence of pre-morbid thoracic imaging for Cases 2 and 3 is a limitation, as subclinical sarcoidosis may have predated COVID infection in these cases, the relatively acute onset of new symptoms after COVID infection is notable.…”

Section: Discussionmentioning

confidence: 67%

See 1 more Smart Citation

Sarcoidosis following COVID infection: A case series

Smith,

Meghji,

Moonim

et al. 2023

Respirology Case Reports

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 57%

Section: Discussionmentioning

confidence: 67%

Sarcoidosis following COVID infection: A case series

Smith,

Meghji,

Moonim

et al. 2023

Respirology Case Reports

View full text Add to dashboard Cite

show abstract

“…In most of the studies, the diagnosis of sarcoidosis was usually made after a long period (more than 5 years) of malignancy diagnosis [9]. However, in a recent study 66% of sarcoidosis cases were diagnosed within the first year of malignancy diagnosis [19]. In the present study, breast (46.7%) and endometrium carcinoma (20%) were the most common malignancies and the mean time interval between two diagnoses was 4±3.6 years ranging between 1 to 12 years.…”

Section: Discussionmentioning

confidence: 99%

Malignancy and sarcoidosis: A single center experience from Turkey

et al. 2023

View full text Add to dashboard Cite

Objective: The relationship between cancer and sarcoidosis has been a research topic for a long time. An increased risk of sarcoidosis and sarcoid-like reactions is suggested in patients with malignant disease. The present study aimed to describe the clinical characteristics and the prognosis of 15 Turkish patients who had a diagnosis of both malignancy and sarcoidosis. Methods: The patients admitted to our department between October 2013 and October 2018 were included in this study. Patient data including, the demographic data, clinical, radiological, pathological findings, and applied treatment modalities were retrieved from hospital database. Results: The study included 14 females and 1 male with a mean age of 53.3±11.4 years. Malignancy was the preceding diagnosis in 13 patients. The mean interval time between two diagnoses was 4±3.6 years. Fourteen patients recovered from their cancer, only 1 patient with relapsed NHL was deceased. The most common type of malignancy was breast (n=7) and endometrium (n=3) carcinoma. Surgery was the primary therapeutic modality in 14 patients. Additionally patients received certain drugs which might contribute to onset of sarcoidosis such as Cyclophosphamide (n=8), Adriamycin (n=8), Trastuzumab (n=2), and Rituximab (n=1). Ten patients were asymptomatic for sarcoidosis and 7 patients had stage I pulmonary sarcoidosis. Two third of the patients (n=10) did not receive any therapy for sarcoidosis. Conclusion: This study involves a few number of patients and according to the analysis of this group the presence of malignancy and sarcoidosis in the same patient might promote good prognosis for both entities. However the onset of sarcoidosis during the follow-up period is a challenging clinical condition and a biopsy is needed for differential diagnosis and management decision. Yet the biopsy might not be enough to differentiate between sarcoidosis and the sarcoid reactions related to malignancy. Future studies are needed to enlighten the underlying pathogenesis.

show abstract

“…The incidence of SLS as a side-effect of treatment with ipilimumab is between 5 and 6.7% [3][4][5][6]. SLS has also been seen as an entity induced by cancer itself as well, in which case it is called paraneoplastic sarcoidosis [7,8].…”

Section: Introductionmentioning

confidence: 99%

Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy

Tijtgat

Schwarze²,

Awada³

et al. 2021

Melanoma Research

View full text Add to dashboard Cite

Treatment with combined BRAF and MEK inhibition is widely accepted as a first-line treatment option for patients with advanced BRAF V600E mutant melanoma. It is generally well-tolerated and has limited side-effects. However, we report a case of a sarcoid-like syndrome induced by treatment with dabrafenib/trametinib (D/T) in a patient with stage IV-M1d melanoma. Sarcoid-like syndrome is a known side-effect of immune checkpointinhibition therapy but has only rarely been described in BRAF/MEK inhibition. However, recognizing this sideeffect is important because of potential misinterpretation as progressive disease and influence on treatment. We describe a 48-year-old female patient who initially presented with solitary brain metastasis and diffuse lung lesions. She was treated with D/T to which she had an initial response in all lesions. One year later, new hilar and mediastinal lymphadenopathies were detected. Imaging was suggestive of the sarcoid-like syndrome. An endoscopic biopsy of the enlarged lymph node showed no melanoma cells. Treatment was continued. Three months later, the patient experienced a drop in hemoglobin, which prompted further investigations into possible occult intestinal metastasis. Video capsule examination revealed a metastatic lesion in the small intestine. A treatment switch to the combination of checkpoint inhibitors nivolumab and ipilimumab successfully treated both lung and small intestine lesions. After the third dose of this combination therapy, she developed an immune-related pneumonitis. Treatment with corticosteroids resolved the pneumonitis and decreased metabolism in the sarcoid-like syndrome. The treatment was not restarted afterward. She remains free of the disease up to today, 2.5 years after diagnosis.

show abstract

Paraneoplastic sarcoidosis: a review

Cited by 12 publications

References 12 publications

Sarcoidosis following COVID infection: A case series

Sarcoidosis following COVID infection: A case series

Malignancy and sarcoidosis: A single center experience from Turkey

Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy

Contact Info

Product

Resources

About